Related Experiment Video

Updated: Oct 8, 2025

A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training
07:50

A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training

Published on: January 29, 2017

9.8K

Effect of Low-Dose Naltrexone on Egyptian Children with Intractable Epilepsy: A Case Series Study

Noha T Abokrysha1, Nirmeen A Kishk1, Amani M Nawito2

  • 1Department of Neurology, Cairo University, Giza, Egypt.

Neurology India
|January 4, 2022
PubMed

Insights

Low-dose naltrexone (LDN) shows promise for treating children with intractable epilepsy, offering a new therapeutic avenue for this challenging neurological condition. This study explores LDN's potential benefits in managing refractory epilepsy in pediatric patients.

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Epilepsy affects 50 million worldwide, with 30% experiencing treatment-refractory seizures.
  • Refractory epilepsy in children poses a significant social and economic burden, particularly in developing nations.
  • Existing antiepileptic drugs have limitations for a substantial patient subset.

Purpose of the Study:

  • To evaluate the efficacy of low-dose naltrexone (LDN) in treating pediatric patients with intractable epilepsy.
  • To investigate the potential immunomodulatory mechanisms of LDN in the context of epileptogenesis.
  • To explore LDN as an alternative treatment for refractory epilepsy in children.

Main Methods:

  • A clinical study assessing the effects of LDN in children diagnosed with intractable epilepsy.
  • Exploration of LDN's role as an immune modulator in neurological disorders.
  • Analysis of potential impact on the epileptogenesis process.

Main Results:

  • Preliminary findings suggest LDN may offer therapeutic benefits for intractable epilepsy in children.
  • LDN's immunomodulatory properties are being investigated for their relevance to epilepsy.
  • Further research is warranted to confirm efficacy and elucidate mechanisms.

Conclusions:

  • Low-dose naltrexone presents a potential novel treatment strategy for pediatric intractable epilepsy.
  • Understanding LDN's immunomodulatory effects could offer new insights into epilepsy treatment.
  • LDN may help alleviate the burden of refractory epilepsy in young patients.

Keywords:
Childrenintractable epilepsylow-dose naltrexonetreatment

More Related Videos

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

2.9K
Anteromesial Temporal Lobectomy for Medically Intractable Temporal Lobe Epilepsy: An Operative Study11:29

Anteromesial Temporal Lobectomy for Medically Intractable Temporal Lobe Epilepsy: An Operative Study

Published on: August 15, 2025

1.1K

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
333
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
573
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
509
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
350
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
11
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
250